文献速递MDS 与骨髓增殖性肿瘤

较低IPSS风险MDS患者接受铁螯合治疗后的总生存:校正患者相关因素并从首次红细胞输血依赖起测量——一项MDS-CAN分析

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
PubMed 文献 · Br J Haematol · 2017-07-05

加拿大MDS注册研究前瞻性纳入239例较低IPSS风险(低危/中危-1)红细胞输血依赖的MDS患者,其中83例接受铁螯合治疗(ICT)。从输血依赖起中位总生存ICT组5.2年 vs 非ICT组2.1年(P<0.0001),多因素分析未接受ICT独立预测较差OS(死亡HR 2.0,P=0.03),配对分析ICT组OS仍更优(P=0.02)。

要点

  • 较低IPSS风险MDS输血依赖患者中,接受ICT者从输血依赖起中位OS为5.2年,未接受ICT者为2.1年(P<0.0001)。
  • 多因素分析中,未接受ICT独立预测较差OS(死亡HR 2.0,P=0.03)。
  • 配对分析校正年龄、修订IPSS、输血依赖严重度等因素后,ICT组OS仍更优(P=0.02)。

核心结论

  • 在这项前瞻性非随机分析中,校正年龄、衰弱、合并症、残疾、修订IPSS、输血依赖严重度、至输血依赖时间及接受疾病修饰药物后,接受ICT与较低IPSS风险MDS患者更优OS相关。
  • 作者认为这提供了额外证据表明ICT可能带来临床获益。

研究设计与样本

  • 加拿大MDS注册研究(MDS-CAN)前瞻性测量衰弱、合并症和残疾。
  • 纳入较低IPSS风险(低危/中危-1)红细胞输血依赖的MDS患者,共239例,其中83例接受ICT。
  • 分析从首次红细胞输血依赖起计算OS,并进行了考虑年龄、修订IPSS、输血依赖严重度、MDS诊断至输血依赖时间及接受疾病修饰药物的配对分析。

主要发现

  • ICT组与非ICT组在衰弱、合并症和残疾方面无差异。
  • 从输血依赖起中位OS:ICT组5.2年 vs 非ICT组2.1年(P<0.0001)。
  • 多因素分析:未接受ICT独立预测较差OS,死亡风险比(HR)2.0(P=0.03)。
  • 配对分析中,ICT组OS仍更优(P=0.02)。

局限性

  • 原文指出该分析为前瞻性、非随机分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Analyses suggest iron overload in red blood cell (RBC) transfusion-dependent (TD) patients with myleodysplastic syndrome (MDS) portends inferior overall survival (OS) that is attenuated by iron chelation therapy (ICT) but may be biassed by unbalanced patient-related factors. The Canadian MDS Registry prospectively measures frailty, comorbidity and disability. We analysed OS by receipt of ICT, adjusting for these patient-related factors. TD International Prognostic Scoring System (IPSS) low and intermediate-1 risk MDS, at RBC TD, were included. Predictive factors for OS were determined. A matched pair analysis considering age, revised IPSS, TD severity, time from MDS diagnosis to TD, and receipt of disease-modifying agents was conducted. Of 239 patients, 83 received ICT; frailty, comorbidity and disability did not differ from non-ICT patients. Median OS from TD was superior in ICT patients (5·2 vs. 2·1 years; P < 0·0001). By multivariate analysis, not receiving ICT independently predicted inferior OS, (hazard ratio for death 2·0, P = 0·03). In matched pair analysis, OS remained superior for ICT patients (P = 0·02). In this prospective, non-randomized analysis, receiving ICT was associated with superior OS in lower IPSS risk MDS, adjusting for age, frailty, comorbidity, disability, revised IPSS, TD severity, time to TD and receiving disease-modifying agents. This provides additional evidence that ICT may confer clinical benefit.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017. PMID: 28677895. doi:10.1111/bjh.14825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。